Skip to main content

Hereditary Angioedema Type I

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Prothya Biosolutions
Prothya BiosolutionsBelgium - Brussels
1 program
1
C1 inhibitor concentratePhase 21 trial
Active Trials
NCT00119431Completed12Est. Mar 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Prothya BiosolutionsC1 inhibitor concentrate

Clinical Trials (1)

Total enrollment: 12 patients across 1 trials

NCT00119431Prothya BiosolutionsC1 inhibitor concentrate

Kinetics, Efficacy and Safety of C1-Esteraseremmer-N

Start: Sep 2005Est. completion: Mar 200612 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.